This article is part of the supplement: Proceedings of the 11th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI): Basic, Epidemiologic, and Clinical Research
Email this article to a friend
Rapamycin reduces primary effusion lymphoma progression by targeting VEGF production and VEGF responses
Infectious Agents and Cancer 2009, 4(Suppl 2):O12 doi:10.1186/1750-9378-4-S2-O12